Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Điểm số NEOS2
NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis
Posted inNeurology news

NEOS2 Score: A Precision Tool for Predicting Treatment Response and Three-Year Functional Recovery in Anti-NMDAR Encephalitis

Posted by MedXY By MedXY 01/28/2026
The international NEOS2 study validates a refined clinical score using five baseline variables to accurately predict short-term immunotherapy response, one-year functional status, and three-year return to work or school in patients with anti-NMDAR encephalitis.
Read More
  • Beyond the Surface: Why Hip Strength and Gait Speed are the New Gold Standards for Monitoring Late-Onset Pompe Disease
  • Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities
  • Beyond Thyroglobulin: Uncovering the Alternative Path for Thyroid Hormone Synthesis
  • Leveling the Playing Field: New Trans-Ancestry Polygenic Risk Score Transforms Type 1 Diabetes Screening
  • Elevated MCP1 and FABP4 in Early PCOS Pregnancy: Metabolic Markers Driven by Adiposity Rather Than Disease Status
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in